Redeye initiates coverage of Nekkar, an industrial technology group offering ocean-based technologie...
Last week Railcare announced a deal that will secure the supply of locomotives for some of its impor...
Redeye comments on the published interim data from the MASCC/AFSOS/ISOO 2004 annual meeting in Lille...
Q2 report due Tuesday, 23 July – many moving parts Key factor looks to be possible imminent Medicare...
22% sales growth (ABGSCe +24%), losses to gradually improve EBIT ests roughly unchanged, 5-8% margin...
Redeye comments on Optomed’s directed share issue, raising approximately EUR7.
Redeye provides a brief comment on the selection of a new drug candidate.
Yesterday evening, Hoylu communicated that a number of shareholders in the Company, including board ...
PMDS has revised the 2026 sales target, which is 160% higher at SEK 260m (SEK 100m) in terms of recu...
Redeye provides its view on the recent financing of SEK80m and the 18-month OPTIMIZE-1 readout, a ph...
Investors House announced today that it has divested its 1/3 stake in Jyväskylän Kukkulan Kehitys Oy...
Yesterday (25 June) we hosted a group presentation with Ferronordic.
Q2e: 6% organic sales growth y-o-y, 9% adj. EBITA margin Expect a softer Q2, partly on further marke...
CoinShares International (CS) är en pionjär och en väletablerad aktör i den framväxande och snabbväx...
Summarising an eventful H1'24 Many players in the Parkinson's therapy game.
Redeye comments on the outcome of the T02 and the directed issue to the top guarantors, which brough...
Redeye provides a comment on the outcome in Respiratorius’ rights issue, announced earlier this afte...
Verve (formerly MGI – Media and Games Invest) has announced the acquisition of Jun Group for €170m (...
The European Medicines Agency (EMA) has approved Cereno Scientific’s Clinical Trial Application (CTA...
Mendus recently presented positive data from two ongoing clinical studies, ADVANCE II and ALISON, at...
